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Despite having the second highest mortality associated with cancer, currently Sorafenib is the only FDA-
approved chemotherapeutic agent available for liver cancer patients which can only improve survival for
few months. In this study, various pyrazolic chalcone analogous compounds were synthesized and
evaluated as potential chemotherapeutic agents for the treatment of hepatocellular carcinoma (HCC).
Modifying the central pyrazole ring at the C(3)-position with different heteroaryl rings and substituting
the C(4)-position of pyrazole with differently substituted chalcone moiety produced fouthy two variant
compounds. For all these compounds, cytotoxicity was evaluated using sulforhodamine B assay and real
time cell growth tracking, respectively. Based on 50% inhibitory concentration (IC50) values, compounds
39, 42, 49, and 52 were shown to exhibit potent cytotoxic activity against all the cancer cell lines tested,
and had better cytotoxic activities than the well-known chemotherapeutic drug 5-FU. Therefore, these
compounds were chosen to be further evaluated in a panel of HCC cell lines. Flow cytometric analysis of
HCC cells treated with compounds 39, 42, 49, and 52 demonstrated that these compounds caused cell
cycle arrest at G2/M phase followed by the apoptotic cell death and impaired cell growth as shown by
real-time cell growth surveillance. Consistent with these results, western blotting of HCC cells treated
with the compounds resulted in molecular changes for cell cycle proteins, where p21 levels were
increased independent of p53 and the levels of the key initiators of mitosis Cyclin B1 and CDK1 were
shown to decrease upon treatment. In conclusion, chalcone derivatives 42 and 52 show potent bio-
activities by modulating the expression of cell-cycle related proteins and resulting in cell-cycle arrest in
the HCC cell lines tested here, indicating that the compounds can be considered as preclinical candidates.
© 2017 Elsevier Masson SAS. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer and the second most frequent cause of cancer-related
mortality [1]. Each year, around five hundred thousand new cases
are diagnosed world-wide and nearly 85% of all cases are from
developing countries. The 5 year survival rate of HCC patients are
low and the incidence of HCC continues to rise (3 fold increase in 20
years). The etiological factors associated with HCC are chronicAtalay), baytas@gazi.edu.tr
served.infection by Hepatitis B virus (HBV) and Hepatitis C virus (HCV),
aflatoxin exposure, chronic alcohol intake, and obesity [2,3].
Currently, Sorafenib, a multikinase inhibitor, is the only drug
approved by FDA for the treatment of HCC which can only prolong
patient survival for a short period of time (2e3 months) [4]. Since
liver cancer cells display inherent resistance to conventional
chemotherapy and radiotherapy, it is critical to develop novel
therapeutic drugs against HCC.
Dysregulation of cell cycle control and cell division is highly
correlated with cancer development, growth and progression. Liver
cancer develops during chronic liver injury which involves immune
response along with cytokines and chemokine activation. Hence
during chronic liver disease, cycles of hepatocyte cell death and
regeneration are induced which engage the activation of cell cycle
proteins [5]. Cyclin-dependent kinases (CDKs) are one of the key
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together with their cyclin partners to phosphorylate the Rb protein
which helps the release of transcription factors to ensure cell cycle
transition. Alterations in the activities of CDKs lead to the trans-
formation of normal cells toward cancerous state [7e12]. Therefore,
design and synthesis of therapeutic agents targeting CDKs have
been the subject of recent drug discovery research studies and a
number of CDK inhibitors have been considered in several clinical
trials [13e16]. Hence Palbociclib, which is a selective inhibitor of
CDK4 and CDK6, was approved by the FDA to be used in combi-
nation with letrozole for the treatment of postmenopausal women
with HER2-negative advanced breast cancer [17e20].
Chalcones, 1,3-diaryl-2-propen-1-ones, are naturally occurring
intermediates of flavonoid compounds [21]. Chalcones have shown
broad range of biological activities such as antioxidant, antibacte-
rial, antifungal, anti-HIV, antileishmanial, antifilarial, antimalarial,
anti-inflammatory, and anticancer properties [22,23]. It has been
determined that many chalcone derivatives exhibit cytotoxic ac-
tivity in various cancer cell lines through different molecular
mechanisms [24,25].
Pyrazoles with their distinctive scaffold possess wide range of
anticancer bioactivities [26e31]. Though more widely known for
their use in analgesic, antipyretic and anti-inflammatory actions,
pyrazoles can also have antileukemic [32,33], antitumor [34,35]
and anti-proliferative [36]. Although the pyrazole skeleton is an
important building block in mediating its biological effects, the
type of peripheral substituents are crucial for their selectivity to-
ward their targets. Studies concerning structureeactivity relation-
ships have shown that the cytotoxic potency of the compounds has
been highly dependent on the substitution types and patterns on
the aryl ring. Thus, 3,4-disubstituted pyrazole analogues, and 3-Fig. 1. Structure of hepatotoxic agents and some CDK inhibitors which are already approved
compounds.(imidazol-2-yl)-4-[2-(pyridin-3-yl)-vinyl]-pyrazoles (1), have been
reported as cyclin-dependent kinase (CDK) inhibitors and have
been shown to inhibit in vitro cellular proliferation in various hu-
man cancer cells [37]. In another study, Huang et al. showed that N-
((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivative 2 [38]
had inhibitory activity on MCF-7 and B16-F10 cell lines with IC50
values of 1.88 and 2.12 mM, respectively. Compound 2 inhibits the
CDK2/cyclin E holoenzyme activities with IC50 of 0.98 mM (Fig. 1).
Recently, (N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-
diphenyl-1H-pyrazole-4-carboxamide derivatives were reported
as CDK1/Cdc2 inhibitors [39].
In our previous studies, we reported 1,3-diarylpyrazole de-
rivatives containing thiophene and pyridine heterocycles as sig-
nificant antiproliferative agents against MCF7, MDA-MB-231, HeLa,
Raji and HL60 human cancer cell lines (3 in Fig. 1) [40,41]. Therefore
considering the limited availability of targeted therapies in liver
cancer, in this study, the cytotoxicities of pyrazolic chalcone de-
rivatives are investigated in order to identify the potential bio-
activities as drug candidates in treatment of HCC. Here we report
the synthesis and the biological activities of a new series of 1,3,4-
trisubstitutedpyrazoles 12e53 in which; i) a heteroaryl moiety
(3-thienyl, 3-(benzo[d][1,3]dioxol-5-yl, 3-pyridyl, 4-pyridyl) is
attached to the central pyrazole ring at position 3; ii) phenyl is
attached to the pyrazole ring at position 1 and iii) chalcone moiety
is attached to the central pyrazole ring at position 4.
2. Results and discussion
2.1. Chemistry
The 1,3-diarylpyrazole chalcone derivatives (12e53) wereor have reached clinical trials for the treatment of cancer; lead CDK inhibitors and title
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4e7were generated by condensing appropriate methyl ketone and
phenylhydrazine in the presence of acetic acid in refluxing ethanol.
The IR spectra of hydrazone 4e7 showed disappearance of the
carbonyl peak that belonged to acetyl group of methyl ketone de-
rivatives. This hydrazone derivative was then reacted with POCl3
and DMF resulting in 1,3-diaryl pyrazoles 8e11 with aldehyde
group at 4 position. 1,3-Diarylpyrazole chalcone analogs 12e53
were prepared by condensation of 1-phenyl-3-heteroaryl-1H-pyr-
azole-4-carboxaldehyde derivatives 8e11 and corresponding
methyl ketones in ethanol solution, applying 40% aqueous NaOH as
a catalyst.
All compounds were purified either by automated flash chro-
matography or recrystallization; or automated flash chromatog-
raphy then recrystallization and checked for purity by elemental
analysis or UPLC (purity was >97%) before being tested in biological
assays. The structures of these compounds were confirmed by
high-resolution mass spectrometry (HRMS), IR, 13C NMR and 1H
NMR spectral data. Elemental analysis results were also provided
for eighteen of the title compounds.2.2. Biological evaluations
2.2.1. Cytotoxicities of the pyrazolic chalcone derivatives in liver
cancer cells
Pyrazolic chalcone derivatives (12e53) were initially screened
against Hepatocellular (Huh7), breast (MCF7) and colon carcinoma
(HCT116) cells. Bioactivities of each compound were evaluated by
sulforhodamine B (SRB) assay. The IC50 values after 72 h of treat-
ment with each molecule were calculated in comparison with the
well known chemotherapeutic agents such as, nucleobase analogue
5-fluorouracil (5-FU) and nucleoside analogue cladribine. IC50
values were in between 0.3 and 29 mM as shown in Table 1.
In general, compounds having thenyl moiety at position 3 on the
pyrazole ring (12e19) displayed great antiproliferative potency on
all cancer cell lines with the exception of the benzo[d][1,3]dioxol-5-
yl chalcone derivative 19. Compounds having methoxy substituent
at positions 3 and 4 or at 2 and 5 on the phenyl chalconic moiety of
the molecules (16, 17) showed IC50 values of 0.4e3.4 mM in Huh7,
MCF7 and HCT116 cell lines.
Replacing the thenyl moiety (12e19) with benzo[d][1,3]dioxol-
5-yl ring (20e31) resulted in a significant decrease in the cytotoxic
activity of the compounds which bears methoxy groups on the
phenyl chalconic moiety especially against Huh7 (6.1e19.0 mM) and
MCF7 (5.8e14.5 mM). Compounds having benzo[d][1,3]dioxol-5-yl
moiety at position 3 on the pyrazole ring and heterocyclic rings
such as 3-thenyl, 3-/2-pyridyl at the chalconic part (27e29) showed
notable antiproliferative activity against Huh7 (3.2e3.4 mM), MCF7Scheme 1. Synthesis of 1,3-diarylpyrazole chalcone derivatives. Reagents and conditions: i.)
4 h iii.) methyl ketone derivatives, NaOH, EtOH.(2.2e4.9 mM) and HCT116 (3.8e8.9 mM) cell lines. Derivatives 30
(having benzo[d] [1,3]dioxol-5-yl moiety at both on the pyrazole
and chalcone part) and 31 (bearing benzo[d][1,3]dioxol-5-yl moiety
at position 3 on the pyrazole and 3-pyrolyl moiety at chalcone part)
had weak activity for all cell lines used in this study (9.2e27.2 mM).
The 3-/4-pyridyl derivatives at 3 position of pyrazole ring
(32e53) displayed very significant antiproliferative activity on all
cancer cell lines (IC50 values of below 7 mM) with the exception of
compound 46 which bears 3-pyrolyl moiety at chalcone part.
Introduction of heterocylic rings at chalcone part as in compounds
33, 34, 35, 36, 46 did not result in any advantage toward the activity
of the compounds. In 3-pyridyl series, regarding the effect of sub-
stitution on the phenyl ring (R) at chalcone side, the 2,4,6-
trimethoxy derivative 39 has remarkable cytotoxic activity
against all tested human cancer cells, especially to Huh7 (Table 1).
Compound 42, the 2,5-dimethoxy derivative were also showed
significant activity against all test cell lines (IC50 values of 1,3 mM
Huh7; 1.5 mM MCF7; 1 mM HCT116). Their analogs in 4-pyridyl se-
ries, compounds 49 and 52were also very active, with IC50 values in
the range of 0.6e2.6 mMagainst all tested cell lines following 72 h of
treatment. Whenwe compared the IC50 values of these compounds
to well-known chemotherapeutic drugs, we observed that they
were lower than 5-FU and comparable to that of cladribine.
Therefore, the compounds which displayed significant cytotoxic
effects (39, 42, 49, 52) were chosen to be further evaluated in a
panel of HCC cell lines composed of Huh7, HepG2, Mahlavu and
SNU-475 cells, MCF12A, normal human breast epithelial cells and
MRC5, human fetal lung fibroblast cells. Our results showed that
pyrazolic chalcone derivatives were cytotoxic to HCC cells, however
they were less cytotoxic to MCF12A and MRC-5 cells. (Table 2).
Additionally, compound 49 had no cytotoxicity on MRC5 cells.
Recent studies have shown that some chalcone derivatives
inhibit cell growth of several human cancer cell lines as tubulin
binding and depolymerizing agents [34]. The chalcone analogs of
some natural products such as combretastatin have been synthe-
sized and developed by Ducki et al. [42]. These chalcone analogs
show potent inhibition of tubulin assembly and possess promising
anticancer activity, and are currently under preclinical evaluation
[43,44]. Based on this information, we analyzed the effect of com-
pounds 12e53 on tubulin polymerization, however no inhibitory
effect on tubulin polymerization was observed (data not shown).2.2.2. Real-time cellular response of hepatocellular carcinoma cells
with 39, 42, 49 and 52 treatment
Time-dependent cytotoxic activities of pyrazole chalcone de-
rivatives were performed with real time cell electronic sensing (RT-
CES) on Huh7, HepG2, Mahlavu and SNU-475 cells. It was shown
that all compounds reduced the growth rate of cells compared toPhenyl hydrazine, acetic acid, ethanol, 2 h reflux. ii.) Dimethyl formamide, POCl3, 50 C,
Table 1
Cytotoxicity of compounds 12e53 and nucleoside analogs 5-FU and cladribine assessed in different human cancer cells.
IC50 (mM)
Compound Ar R Huh7 MCF7 HCT116
12 4.7 ± 0.74 1.9 ± 0.30 5.1 ± 0.55
13 3.6 ± 0.58 4.9 ± 0.01 3.2 ± 0.65
14 6.1 ± 0.03 2.7 ± 0.54 5.2 ± 1.47
15 4.2 ± 0.47 7.4 ± 0.59 5.8 ± 1.57
16 2.9 ± 0.54 2.8 ± 0.51 1.6 ± 0.32
17 2.1 ± 1.37 0.4 ± 0.25 3.4 ± 0.48
18 3.0 ± 0.54 9.0 ± 1.05 2.2 ± 0.43
19 22.6 ± 0.87 5.3 ± 0.22 12.2 ± 0.78
20 10.5 ± 0.33 11.1 ± 0.59 1.16 ± 0.01
21 11.7 ± 0.53 10.9 ± 1.25 8.3 ± 1.07
22 6.7 ± 0.21 11.5 ± 0.32 10.8 ± 0.98
23 10.8 ± 0.8 7.4 ± 0.17 3.2 ± 0.54
24 15.4 ± 0.9 11.7 ± 0.37 11.4 ± 0.01
25 6.1 ± 0.11 5.8 ± 0.82 1.3 ± 0.36
26 19.0 ± 1.01 14.5 ± 0.6 8.6 ± 0.9
27 3.2 ± 0.44 4.9 ± 0.04 8.9 ± 0.71
(continued on next page)
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Table 1 (continued )
IC50 (mM)
Compound Ar R Huh7 MCF7 HCT116
28 3.4 ± 0.71 4.1 ± 0.04 6.7 ± 0.47
29 3.4 ± 0.9 2.2 ± 0.55 3.8 ± 0.20
30 9.9 ± 0.77 17.5 ± 0.7 27.2 ± 1.0
31 9.2 ± 0.95 9.9 ± 0.27 20.3 ± 0.56
32 1.7 ± 0.51 0.5 ± 0.04 1.3 ± 0.9
33 6.4 ± 0.8 4.2 ± 0.57 2.1 ± 0.35
34 6.7 ± 0.31 5.6 ± 0.77 1.8 ± 0.67
35 3.3 ± 0.78 6.9 ± 0.05 7.4 ± 1.02
36 3.2 ± 1.07 2.6 ± 0.00 6.4 ± 0.24
37 2.3 ± 0.49 4.1 ± 0.05 2.0 ± 0.71
38 1.9 ± 0.53 14.5 ± 0.06 8.6 ± 0.35
39 0.5 ± 0.17 1.0 ± 0.50 0.3 ± 0.15
40 2.3 ± 1.43 1.4 ± 0.14 1.1 ± 0.46
41 3.1 ± 0.32 1.7 ± 0.84 4.3 ± 1.20
42 1.3 ± 0.16 1.5 ± 0.52 1.0 ± 0.50
43 2.4 ± 0.56 2.3 ± 0.02 1.3 ± 0.75
44 2.2 ± 0.5 1.5 ± 0.58 1.1 ± 0.60
45 0.4 ± 0.14 0.8 ± 0.02 5.3 ± 0.90
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Table 1 (continued )
IC50 (mM)
Compound Ar R Huh7 MCF7 HCT116
46 28.8 ± 1.85 13.6 ± 1.47 15.7 ± 0.66
47 1.8 ± 0.51 3.4 ± 0.44 3.1 ± 0.88
48 3.5 ± 0.07 3.5 ± 0.04 0.3 ± 0.29
49 2.6 ± 0.58 1.6 ± 0.66 0.6 ± 0.18
50 3.7 ± 0.03 3.3 ± 0.04 1.3 ± 0.86
51 2.0 ± 0.25 4.3 ± 0.07 1.2 ± 0.32
52 1.7 ± 0.21 1.4 ± 0.38 0.9 ± 0.23
53 4.4 ± 0.52 8.8 ± 0.18 4.4 ± 0.52
5-FU 21.0 ± 0.75 1.4 ± 0.26 18.4 ± 1.1
Cladribine 1.8 ± 0.43 2.0 ± 0.11 0.3 ± 0.15
NI: No inhibition.
Table 2
IC50 values of compounds 39, 42, 49 and 52 for HCC cell lines (Huh7, HepG2,
Mahlavu and SNU-475) and in epithelial cells (MCF12A and MRC-5).
Compound IC50 Values (mM)
Huh7 HepG2 Mahlavu SNU-475 MCF12A MRC-5
39 0.5 ± 0.2 1.4 ± 0.2 1.1 ± 0.2 0.8 ± 0.1 1.2 ± 0.5 1.3 ± 0.6
42 1.3 ± 0.2 3.4 ± 0.8 2.0 ± 0.3 1.9 ± 0.1 2.4 ± 0.8 2.7 ± 0.9
49 2.6 ± 0.6 1.7 ± 0.1 1.1 ± 0.1 1.4 ± 0.3 8.2 ± 0.6 NI
52 1.7 ± 0.9 4.8 ± 0.3 1.6 ± 0.2 2.0 ± 0.3 3.0 ± 0.6 3.1 ± 0.9
NI: No inhibition in cell growth.
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that the growth inhibition was due to cell cycle arrest, where the
cells were neither proliferating nor dying, whereas the cells treated
with DMSO continued to proliferate until they reach confluence
[45].
2.2.3. Characterization of cell death mechanism induced by
pyrazolic chalcone derivatives
HepG2 and SNU475 cells were treated with the compounds for
48 h. In order to determine the death mechanism induced by pyr-
azolic chalcone derivatives, fluorescent microscopy using Annexin
V stainingwas employed. Compared to DMSO controls, cells treated
with all four of the chosen compounds were detached from thesurface (Suppl. Fig. 5) and cells with condensed nuclei were positive
for Annexin V staining, which indicates apoptotic cell death
(Fig. 3a). After 24 h of treatment, PARP cleavage was observed in
poorly-differentiated SNU475 cells by western blot analysis
compared to well-differentiated HepG2 cells (Fig. 3b) [46].2.2.4. Induction of G2/M cell cycle arrest by the pyrazolic chalcone
derivatives
Since the pattern of cell growth observed from the real-time cell
analysis suggested the induction of cell cycle arrest flow cytometry
analysis using propidium iodide (PI) staining of DNA was then
performed. Following 48hrs of treatment entry to G2/M phase was
observed to be increased, which subsequently caused entry into
sub-G1 phase at 72 h, especially with compounds 39, 42 and 52
(Fig. 4). Altogether, our results indicate that pyrazolic chalcone
derivatives induce cell cycle arrest at the G2/M phase which was
followed by apoptotic cell death in hepatocellular carcinoma cell
lines.2.2.5. Analysis of targeted cellular pathways
Cell cycle-related proteins more specifically those that are
involved in the G2/M phase were analyzed by western blotting
(Fig. 5). CyclinB1 and CDK1 complex was previously shown to be
critical for the progression of cells in and out of M phase of the cell
Fig. 2. RT-CES analysis of HCC cell lines treated with compounds 39, 42, 49 and 52 and with DMSO control (0.1%) at IC100 concentrations for 48 h.
Fig. 3. Detection of apoptosis using fluorescent microscopy and western blotting. A. Annexin V staining of HepG2 and SNU-475 cells treated with compounds 39, 42, 49 and 52 for
48 h with IC100 concentrations. Condensed nuclei appear blue DAPI staining co-localize with Annexin V stained cells appear green. B. PARP cleavage after 24 h of treatment as shown
by western blot analysis. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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52, levels of CDK1 were shown to decrease by half in HepG2 cells,
whereas a minor change was observed for SNU475 cells. Phospho-
Cyclin B1 levels were shown to decrease by half in HepG2 cells,
although there was a slight reduction in Cyclin B1 protein levels. It
is well known that phosphorylation of Ser147 is necessary for the
nuclear translocation of Cyclin B1 during prophase. Therefore, our
results are indicate that pyrazole chalcone derivatives could be
involved in a mechanism inducing inhibition of Cyclin B1 phos-
phorylation, which results in a decreased amount of active CyclinB1, translocating into the nuclei. In addition to this, levels of p21,
known to inhibit the activation of CyclinB1/CDK1 complex, were
shown to increase by 5e6 fold in HepG2 cells and nearly 2 fold in
SNU475 cells upon treatment with compounds 42 and 52. It was
further explored that this change in p21 levels were independent of
p53 levels. The phospho-Rb levels were also found to be decreased,
further impairing the cell cycle machinery, which could be the
implication of secondary effects of pyrazolic chalcone derivatives
on cell cycle.
Fig. 4. Cell cycle analysis of HepG2 and SNU475 cells after treatment with compounds 39, 42, 49 and 52 and DMSO controls following 24 h, 48 h, and 72 h of treatment.
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In this study, we synthesized a series of pyrazolic chalcone de-
rivatives and evaluated their antiproliferative activities against
human cancer cell lines in comparison with clinically used che-
motherapeutics such as 5-FU and Cladribine. The preliminary
structure bioactivity relations in these compounds have been
established and discussed in results section in detail. The central
pyrazole ring was modified at the C(3)-position with different
heteroaryl rings and substituted at the C(4)-position with differ-
ently substituted chalconemoiety. Based on preliminary screenings
the benzo[d][1,3]dioxol-5-yl ring (20e31) was not tolerated and
resulted in mostly inactive or weak inhibitory compounds. Modi-
fications of C(3)-position of central pyrazole ring with 3-/4-pyridyl
moiety improved the bioactivity bearing more potent cytotoxic
compounds. Therefore compounds 39, 42, 49, and 52 were the
most effective derivatives which displayed antiproliferative activity
with IC50 values smaller than 5 mM against HCC cells used here.
Moreover, these compounds were less active on transformed and
normal cells (MCF12A and MRC-5). By further investigating their
molecular effectors, we showed that compounds 42 and 52 caused
cell cycle arrest at the G2/M phase and induced apoptotic cell death
(as summarized in Fig. 6). Moreover, decrease in levels of phospho-
cyclin B1 at the Ser147 residue upon treatment is worth exploring,
since it could provide further information about the mechanism of
action of the compounds on cancer cells. Future studies can eval-
uate the detailed cellular networks that are affected by the use ofhigh throughput genomic screening methods such as tran-
scriptome analysis with next-generation sequencing in the pres-
ence of selected compounds. This may allow to identify molecular
targets involved in cell cycle for eventual drug design and devel-
opment in cancer.4. Experimental
4.1. Chemistry
Melting points were determined with an SMP-II Digital Melting
Point Apparatus and are uncorrected (Schorpp Geaetetechnik,
Germany). IR spectra were obtained using a Perkin Elmer Spectrum
400 FTIR/FTNIR spectrometer equipped with a Universal ATR
Sampling Accessory. 1H NMR and 13C NMR spectrawere recorded in
CDCl3 or DMSO-d6 on a VarianMercury 400MHz High Performance
Digital FT-NMR spectrometer at the NMR facility of the Faculty of
Pharmacy, Ankara University or on a Varian Mercury 300 MHz FT-
NMR spectrometer at the NMR facility of FARGEM (Pharmaceutical
Research and Development Center) Inc. using tetramethylsilane as
the internal standard. All chemical shifts were recorded as d (ppm).
High resolution mass spectra data (HRMS) were collected using a
Waters LCT Premier XE Mass Spectrometer (high sensitivity
orthogonal acceleration time-of-flight instrument) using ESI (þ)
method. The instrument was coupled to an AQUITY Ultra Perfor-
mance Liquid Chromatography system (Waters Corporation, Mil-
ford, MA, USA). Elemental analyses were performed with a LECO-
Fig. 5. Representative images from three independent western blot analysis of G2/M arrest proteins in whole lysates of HepG2 and SNU-475 cells treated with compounds 39, 42, 49
and 52 in IC100 concentrations for 24 h. Graphs demonstrate comparative analysis of protein levels in the presence of compounds normalized to DMSO controls.
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Ankara University. Flash chromatography was performed with a
Combiflash®Rf automated flash chromatography system with
RediSep columns (Teledyne-Isco, Lincoln, NE, USA) using DCM-
MeOH, hexane-EtOAc or MeOH-EtOAc solvent gradients.
4.1.1. General procedure for 1,3-diarylpyrazole chalcone synthesis
To a stirred solution of 1,3-diaryl-1H-pyrazole-4-
carboxaldehyde (1 mmol) and corresponding methyl ketone
(1.05 mmol) in ethanol (5 ml), an aqueous solution of 40% NaOH
(2 ml) was added. The resulting solutionwas heated to 60 C for 4 h
and then allowed to stand overnight at room temperature with
continuous stirring. The reaction mixture was poured into water
and precipitate was collected by filtration, washed with 50%
ethanol, dried, and purified by flash chromatography or
recrystallization.
4.1.2. (E)-1-phenyl-3-(1-phenyl-3-(thiophen-3-yl)-1H-pyrazol-4-
yl)prop-2-en-1-one (CAS No: 303773-77-5) (12)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 76%, mp 138e139C; IR (FTIR/FTNIR-ATR):
1657 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.27 (1H, s),
7.94e7.93 (2H, m), 7.90 (1H, d, J ¼ 15.6 Hz), 7.71 (2H, d, J ¼ 9.9 Hz),
7.59e7.58 (1H, m), 7.54e7.37 (7H, m), 7.33 (1H, d, J ¼ 15.9 Hz), 7.27
(1H, d, J ¼ 7.5 Hz). 13C NMR (DMSO-d6, 400 MHz) d: 188.68, 148.72,
138.89, 137.67, 134.08, 133.01, 132.64, 129.66, 128.77, 128.57, 128.19,
127.51, 127.23, 127.10, 124.69, 121.39, 118.60, 117.89. HRMS (m/z):
[MþH]þ calcd. for C22H17N2OS 357.1062, found 357.1064.
4.1.3. (E)-3-(1-phenyl-3-(thiophen-3-yl)-1H-pyrazol-4-yl)-1-
(3,4,5-trimethoxyphenyl)prop-2-en-1-one (13)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 21%, mp 167e168C; IR (FTIR/FTNIR-ATR):1651 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.25 (1H, s), 7.89
(1H, d, J ¼ 15.6 Hz), 7.71 (2H, d, J ¼ 8.7 Hz), 7.60e7.58 (1H, m),
7.46e7.38 (4H, m), 7.31 (1H, s), 7.25 (1H, d, J ¼ 15.6 Hz), 7.19 (2H, s),
3.86 (9H, s).13C NMR (DMSO-d6, 400 MHz) d:187.46, 152.91, 148.68,
141.97, 138.89, 133.89, 133.06, 132.72, 129.70, 128.72, 127.57, 127.27,
127.17, 124.77, 121.26, 118.77, 117.89, 106.01, 60.21, 56.23. HRMS (m/
z): [MþH]þ calcd. for C25H23N2O4S 447.1379, found 447.1384.4.1.4. (E)-3-(1-phenyl-3-(thiophen-3-yl)-1H-pyrazol-4-yl)-1-
(2,4,6-trimethoxyphenyl)prop-2-en-1-one (14)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 81%, mp 162.5e163.5 C; IR (FTIR/FTNIR-
ATR): 1626 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.14 (1H, s),
7.67 (2H, d, J ¼ 7.8 Hz), 7.48e7.26 (6H, m), 7.19 (1H, d, J ¼ 5.1 Hz),
6.73 (1H, d, J ¼ 16.2 Hz), 6.09 (2H, s), 3.78 (3H, s), 3.72 (6H, s). 13C
NMR (DMSO-d6, 400 MHz) d: 193.13, 161.89, 157.85, 148.11, 138.89,
134.47, 132.70, 129.61, 128.72, 128.31, 127.28, 127.16, 127.02, 123.99,
118.62, 117.21, 110.80, 90.91, 55.77, 55.47. HRMS (m/z): [MþH]þ
calcd. for C25H23N2O4S 447.1379, found 447.1360.4.1.5. (E)-3-(1-phenyl-3-(thiophen-3-yl)-1H-pyrazol-4-yl)-1-
(2,3,4-trimethoxyphenyl)prop-2-en-1-one (15)
Purified by recrystallization of ethyl acetate and hexane. Yield
23%, mp 90.5e91 C; IR (FTIR/FTNIR-ATR): 1649 cm1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 8.22 (1H, s), 7.78e7.69 (3H, m), 7.59e7.58
(1H, m), 7.46e7.35 (5H, m), 7.30e7.24 (2H, m), 6.71e6.68 (1H, d,
J ¼ 8.7 Hz), 3.86 (6H, s), 3.82 (3H, s). 13C NMR (DMSO-d6, 400 MHz)
d: 190.05, 156.39, 152.60, 148.50, 141.64, 138.90, 133.22, 132.71,
129.60, 128.30, 127.47, 127.20, 127.04, 126.32, 125.93, 124.94, 124.57,
118.70, 117.66, 107.88, 61.80, 60.53, 56.07. HRMS (m/z): [MþH]þ
calcd. for C25H23N2O4S 447.1379, found 447.1362.
Fig. 6. Representation of molecular mechanisms initiated by pyrazolic chalcone de-
rivatives (42 and 52). Upon treatment activation of p21 is initiated independent of p53,
which then inhibits CDK1 and Cyclin B1 to form a complex resulting in cell cycle arrest
at G2/M phase followed by cell death.
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1H-pyrazol-4-yl)prop-2-en-1-one (16)
Purified by recrystallization of ethyl acetate and hexane. Yield
62%, mp 151e152 C; IR (FTIR/FTNIR-ATR): 1650 cm1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 8.26 (1H, s), 7.88 (1H, d, J ¼ 15.6 Hz), 7.72
(2H, d, J ¼ 8.1 Hz), 7.60e7.53 (3H, m), 7.46e7.36 (3H, m), 7.31e7.26
(2H, m), 7.19 (1H, S), 6.85 (1H, d, J ¼ 8.1 Hz), 3.90 (6H, s).13C NMR
(DMSO-d6, 400 MHz) d: 186.89, 153.17, 148.82, 148.59, 138.94,
133.03, 132.77, 130.58, 129.68, 128.46, 127.54, 127.23, 127.07, 124.64,
122.91, 121.35, 118.65, 118.01, 110.87, 110.66, 55.78, 55.59. HRMS (m/
z): [MþH]þ calcd. for C24H21N2O3S 417.1273, found 417.1273.
4.1.7. (E)-1-(2,5-dimethoxyphenyl)-3-(1-phenyl-3-(thiophen-3-yl)-
1H-pyrazol-4-yl)prop-2-en-1-one (17)
Purified by recrystallization of ethyl acetate and hexane. Yield
73%, mp 105.5e106 C; IR (FTIR/FTNIR-ATR): 1649 cm-1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 8.18 (1H, s), 7.74 (1H, s), 7.71e7.68 (2H,
m), 7.55e7.53 (2H, m), 7.45e7.34 (1H, m), 7.27 (2H, t, J¼ 7.5 Hz), 7.19
(1H, d, J ¼ 5.1 Hz), 7.15 (1H, s), 7.09 (1H, d, J ¼ 3 Hz), 6.96 (1H, d,
J ¼ 3.3 Hz), 6.93 (1H, d, J ¼ 3 Hz), 3.77 (3H, s), 3.73 (3H, s).13C NMR
(DMSO-d6, 400 MHz) d: 191.78, 153.00, 151.49, 148.49, 138.88,
133.63, 132.69, 129.61, 129.44, 128.50, 127.44, 127.19, 127.05, 126.29,
124.52, 118.69, 118.02, 117.58, 113.97, 113.64, 56.30, 55.54. HRMS (m/
z): [MþH]þ calcd. for C24H21N2O3S 417.1273, found 417.1256.
4.1.8. (E)-1-(2,4-dimethoxyphenyl)-3-(1-phenyl-3-(thiophen-3-yl)-
1H-pyrazol-4-yl)prop-2-en-1-one (18)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 60%, mp 180.5e181 C; IR (FTIR/FTNIR-ATR):1642 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.17 (1H, s),
7.78e7.66 (4H, m), 7.58e7.56 (1H, m), 7.46e7.24 (6H, m), 6.50
(1H,d, J ¼ 10.5 Hz), 6.42 (1H, s), 3.80 (6H, s). 13C NMR (DMSO-d6,
400 MHz) d: 189.28, 163.74, 159.95, 148.40, 138.93, 132.81, 131.87,
131.75, 129.60, 128.28, 127.52, 127.14, 126.98, 126.55, 124.56, 121.45,
118.70, 117.85, 105.85, 98.53, 55.92, 55.57. HRMS (m/z): [MþH]þ
calcd. for C24H21N2O3S 417.1273, found 417.1267.
4.1.9. (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(1-phenyl-3-(thiophen-3-
yl)-1H-pyrazol-4-yl)prop-2-en-1-one (19)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 81% as a colorless oil; IR (FTIR/FTNIR-ATR):
1646 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 8.31 (1H, s), 7.93
(1H, d, J ¼ 15.6 Hz), 7.78 (2H, d, J ¼ 8 Hz), 7.65e7.64 (1H, m), 7.59
(1H, dd, J ¼ 2 Hz, J ¼ 8 Hz), 7.52e7.44 (5H, m), 7.36e7.32 (2H, m),
6.88 (1H, d, J ¼ 8.4 Hz), 6.06 (2H, s). 13C NMR (DMSO-d6, 400 MHz)
d: 186.43, 151.47, 148.62, 148.01, 138.92, 133.35, 132.70, 132.32,
129.67, 128.42, 127.49, 127.22, 127.08, 124.61, 124.57, 121.27, 118.59,
117.99, 108.15, 107.65, 102.09. HRMS (m/z): [MþH]þ calcd. for
C23H17N2O3S 401.0960, found 401.0954.
4.1.10. (E)-3-(3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)-1-phenylprop-2-en-1-one (20)
Purified by column flash chromatography (0% / 30% ethyl ac-
etate in hexane). Yield 95%, mp 163.5e164 C; IR (FTIR/FTNIR-ATR):
1662 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.27 (1H, s), 7.90
(2H, d, J ¼ 8.7 Hz), 7.79 (1H, d, J ¼ 15.6 Hz), 7.72 (2H, d, J ¼ 9.6 Hz),
7.51e7.40 (5H, m), 7.34e7.28 (2H, m), 7.14e7.07 (2H, m), 6.86 (1H, d,
J ¼ 8.1 Hz), 5.96 (2H, s). 13C NMR (DMSO-d6, 400 MHz) d: 189.22,
153.16, 148.28, 148.21, 139.40, 138.15, 134.80, 133.50, 130.14, 129.24,
129.18, 128.66, 127.57, 126.17, 122.91, 121.74, 119.10, 118.10, 109.14,




Purified by column flash chromatography (0% / 30% ethyl ac-
etate in hexane). Yield 53%, mp 163.5e164 C; IR (FTIR/FTNIR-
ATR):1656 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.32 (1H, s),
7.89e7.77 (3H, m), 7.52e7.14 (8H, m), 6.93 (1H, d, J ¼ 8.1 Hz), 6.02
(2H, s), 3.93 (9H, s). 13C NMR (DMSO-d6, 400MHz) d: 187.52,152.90,
152.65, 147.80, 147.72, 141.96, 138.92, 134.11, 133.06, 129.68, 128.80,
127.13, 125.79, 122.47, 121.12, 118.77, 117.60, 108.66, 108.54, 106.00,




Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 40%, mp 205e205.5C; IR (FTIR/FTNIR-ATR):
1650 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.15 (1H, s), 7.67
(2H, d, J ¼ 7.8 Hz), 7.44e7.35 (3H, m), 7.29e7.24 (1H, m), 7.05e7.02
(2H, m), 6.81e6.67 (2H, m), 6.07 (2H, s), 5.94 (2H, s), 3.77 (3H, s),
3.73 (6H, s).13C NMR (DMSO-d6, 400 MHz) d: 193.40, 161.81, 157.81,
151.95, 147.72, 147.71, 138.92, 135.15, 129.61, 128.60, 128.46, 127.01,
125.59, 122.02, 118.64, 116.84, 110.53, 108.56, 108.16, 101.40, 90.84,




Purified by recrystallization of ethyl acetate and hexane. Yield
27%, mp 144.5e145 C; IR (FTIR/FTNIR-ATR): 1657 cm1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 8.22 (1H, s), 7.72e7.65 (3H, m), 7.45e7.38
(3H, m), 7.29e7.22 (2H, m), 7.13e7.07 (2H, m), 6.85 (1H, d,
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(3H, s). 13C NMR (DMSO-d6, 400 MHz) d: 190.03, 156.38, 152.63,
152.45, 147.75, 147.69, 141.64, 138.93, 133.46, 129.60, 128.49, 127.01,
126.30, 125.77, 124.94, 122.40, 118.71, 117.37, 108.61, 108.50, 107.83,
101.37, 61.80, 60.53, 56.06. HRMS (m/z): [MþH]þ calcd. for
C28H25N2O6 485.1713, found 485.1711.
4.1.14. (E)-3-(3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (24)
Purified by column flash chromatography (0% / 30% ethyl ac-
etate in hexane). Yield 45%, mp 158.5e159 C; IR (FTIR/FTNIR-ATR):
1649 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.26 (1H, s), 7.79
(1H, d, J ¼ 15.3 Hz), 7.71 (2H, d, J ¼ 7.8 Hz), 7.45e7.40 (2H, m),
7.56e7.52 (2H, m), 7.33 (1H, d, J ¼ 15.6 Hz), 7.27 (1H, d, J ¼ 7.5 Hz),
7.14 (1H, s), 7.10 (1H, d, J ¼ 9.6 Hz), 6.88 (1H, s), 6.84 (1H, d,
J ¼ 8.4 Hz), 5.96 (2H, s), 3.89 (6H, s). 13C NMR (DMSO-d6, 400 MHz)
d: 186.93, 153.15, 152.53, 148.81, 147.76, 147.72, 138.96, 133.25,
130.56, 129.66, 128.56, 127.04, 125.81, 122.89, 122.41, 121.19, 118.64,
117.71, 110.86, 110.66, 108.65, 108.50, 101.38, 55.77, 55.57. HRMS (m/
z): [MþH]þ calcd. for C27H23N2O5 455.1607, found 455.1606.
4.1.15. (E)-3-(3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)-1-(2,5-dimethoxyphenyl)prop-2-en-1-one (25)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 28%, mp 125e126C; IR (FTIR/FTNIR-ATR):
1652 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.18 (1H, s),
7.71e7.68 (2H, d, J¼ 9.9 Hz), 7.60 (1H, d, J¼ 16.2 Hz), 7.44e7.39 (2H,
m), 7.29e7.24 (1H, m), 7.16 (1H, s), 7.11 (1H, m), 7.08e7.05 (2H, m),
6.94 (1H, d, J ¼ 3.3 Hz), 6.86e6.82 (2H, m), 5.96 (2H, s), 3.77 (3H, s),
3.73 (3H, s). 13C NMR (DMSO-d6, 400MHz) d: 192.04,153.00,152.42,
151.37, 147.76, 147.69, 138.91, 134.15, 129.60, 129.41, 128.64, 127.04,
126.16, 125.71, 122.33, 118.71, 117.92, 117.24, 113.92, 113.55, 108.56,
108.44, 101.39, 56.26, 55.54. HRMS (m/z): [MþH]þ calcd. for
C27H23N2O5 455.1607, found 455.1608.
4.1.16. (E)-3-(3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one (26)
Purified by recrystallization of ethyl acetate and hexane. Yield
28%, mp 154,8e155.3 C; IR (FTIR/FTNIR-ATR): 1645 cm1 (C]O).
1H NMR (CDCl3, 300 MHz) d: 8.17 (1H, s), 7.71e7.62 (4H, m),
7.44e7.39 (2H, m), 7.29e7.22 (2H, m), 7.13e7.07 (2H, m), 6.84 (1H,
d, J ¼ 8.1 Hz), 6.49 (1H, d, J ¼ 10.8 Hz), 6.14 (1H, s), 5.95 (2H, s), 3.08
(6H, s). 13C NMR (DMSO-d6, 400 MHz) d: 189.51, 163.68, 159.87,
152.33, 147.70, 147.65, 138.96, 132.19, 131.84, 129.57, 128.39, 126.94,
126.41, 125.89, 122.37, 121.43, 118.70, 117.53, 108.60, 108.50, 105.81,
101.36, 98.51, 55.87, 55.54. HRMS (m/z): [MþH]þ calcd. for
C27H23N2O5 455.1607, found 455.1607.
4.1.17. (E)-3-(3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)-1-(thiophen-3-yl)prop-2-en-1-one (27)
Purified by recrystallization of ethyl acetate and hexane. Yield
56%, mp 138.5e139.5 C; IR (FTIR/FTNIR-ATR): 1659 cm1 (C]O).
1H NMR (CDCl3, 300 MHz) d: 8.25 (1H, s), 8.01e8.02 (1H, m), 7.78
(1H, d, J ¼ 15.6 Hz), 7.70 (2H, d, J ¼ 8.4 Hz), 7.56 (1H, d, J ¼ 6 Hz),
7.45e7.39 (2H, m), 7.30e7.06 (5H, m), 6.86 (1H, d, J ¼ 7.8 Hz), 5.96
(2H, s). 13C NMR (DMSO-d6, 400 MHz) d: 182.77, 152.57, 147.78,
147.72, 142.90, 138.93, 133.31, 133.18, 129.68, 128.46, 127.75, 127.10,
126.93, 125.72, 122.65, 122.39, 118.65, 117.58, 108.66, 108.46, 101.38.




Purified by recrystallization of ethyl acetate and hexane. Yield
83%, mp 188.5e189.2 C; IR (FTIR/FTNIR-ATR): 1650 cm1 (C]O).1H NMR (CDCl3, 300 MHz) d: 8.88 (1H, d, J ¼ 4.4 Hz), 8.42 (1H, s),
8.14e7.72 (6H, m), 7.46e7.28 (4H, m), 7.16 (1H, s), 7.12 (1H, d,
J ¼ 9.9 Hz), 6.88 (1H, d, J ¼ 7.8 Hz), 5.97 (2H, s). 13C NMR (DMSO-d6,
400 MHz) d: 188.58, 153.57, 152.91, 149.01, 147.84, 147.75, 138.95,
137.71, 134.72, 129.59, 128.71, 127.50, 127.04, 125.69, 122.56, 122.48,
120.20, 118.75, 117.63, 108.68, 108.61, 101.41. HRMS (m/z): [MþH]þ
calcd. for C24H18N3O3 396.1348, found 396.1344.4.1.19. (E)-3-(3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)-1-(pyridin-3-yl)prop-2-en-1-one (29)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 10%, mp 174e176.5 C; IR (FTIR/FTNIR-ATR):
1660 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 9.17 (1H, s), 8.78
(1H, dd, J ¼ 1.6 Hz, J ¼ 4.8 Hz), 8.36 (1H, s), 8.25 (1H, dt, J ¼ 2 Hz,
J ¼ 8 Hz), 7.93e7.89 (1H, d, J ¼ 15.6 Hz), 7.79 (2H, d, J ¼ 7.6 Hz)
7.52e7.48 (2H, m), 7.46e7.42 (1H, m), 7.38e7.32 (2H, m), 7.19 (1H,
s), 7.14 (1H, dd, J¼ 1.6 Hz, J¼ 7.6 Hz), 6.94 (1H, d, J¼ 8 Hz), 5.97 (2H,
s). 13C NMR (DMSO-d6, 400 MHz) d: 187.82, 153.28, 152.86, 149.40,
147.86, 147.77, 138.88, 135.62, 135.01, 132.90, 129.72, 128.92, 127.20,
125.58, 123.99, 122.46, 120.95, 118.65, 117.53, 108.69, 108.49, 101.41.
HRMS (m/z): [MþH]þ calcd. for C24H18N3O3 396.1348, found
396.1330.4.1.20. (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(3-(benzo[d] [1,3]dioxol-
5-yl)-1-phenyl-1H-pyrazol-4-yl)prop-2-en-1-one (30)
Purified by recrystallization of ethyl acetate and hexane. Yield
51%, mp 169.5e170 C; IR (FTIR/FTNIR-ATR): 1644 cm1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 8.25 (1H, s), 7.78 (1H, d, J ¼ 16.5 Hz), 7.71
(2H, d, J ¼ 7.8 Hz), 7.53 (1H, d, J ¼ 9.9 Hz), 7.45e7.40 (3H, m),
7.30e7.07 (4H, m), 6.84 (1H, qd, J ¼ 1.6 Hz, J ¼ 9.3 Hz), 6.00 (2H, s),
5.96 (2H, s). 13C NMR (DMSO-d6, 400MHz) d: 186.44, 152.56,151.44,
147.99, 147.76, 147.71, 138.94, 133.55, 132.32, 129.65, 128.53, 127.04,
125.75, 124.54, 122.38, 121.09, 118.58, 117.71, 108.63, 108.46, 108.27,
107.65, 102.08, 101.37. HRMS (m/z): [MþH]þ calcd. for C26H19N2O5
439.1294, found 439.1304.4.1.21. (E)-3-(3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)-1-(1H-pyrrol-3-yl)prop-2-en-1-one (31)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 11%, mp 200e203C; IR (FTIR/FTNIR-ATR):
1638 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 9.50 (1H, s), 8.30
(1H, s), 7.84 (1H, d, J ¼ 15.6 Hz), 7.78 (2H, d, J ¼ 7.6 Hz), 7.50e7.47
(2H, m), 7.36e7.32 (1H, m), 7.21e7.16 (3H, m), 7.08 (1H, s),
6.95e6.92 (3H, m), 6.34e6.32 (1H, m), 6.03 (2H, s). 13C NMR
(DMSO-d6, 400MHz) d: 177.61,152.27,147.69,139.01,132.99,130.71,
130.53, 129.66, 128.16, 126.97, 126.24, 125.92, 122.72, 122.38, 118.58,
117.75, 116.63, 110.09, 108.66, 108.50, 101.36. HRMS (m/z): [MþH]þ
calcd. for C23H18N3O3 384.1348, found 384.1347.4.1.22. (E)-3-(1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-4-yl)-1-
(thiophen-3-yl)prop-2-en-1-one (32)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 82%, mp 172e173C; IR (FTIR/FTNIR-ATR):
1655 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 8.99 (1H, d,
J¼ 1.6 Hz), 8.69 (1H, dd, J¼ 1.6 Hz, J¼ 5.2 Hz), 8.37 (1H, s), 8.07 (1H,
dd, J ¼ 1.2 Hz, J ¼ 2.8 Hz), 8.01 (1H, dt, J ¼ 2 Hz, J ¼ 8 Hz), 7.84e7.79
(3H, m), 7.61 (1H, dd, J ¼ 1.2 Hz, J ¼ 4.8 Hz), 7.54e7.50 (2H, m),
7.45e7.35 (3H, m), 7.23 (1H, d, J ¼ 16.4 Hz). 13C NMR (DMSO-d6,
400 MHz) d: 182.69, 149.93, 149.68, 148.73, 142.81, 138.84, 135.77,
133.47, 132.40, 129.74, 128.88, 127.91, 127.82, 127.39, 126.92, 123.94,
123.30, 118.81, 118.14. HRMS (m/z): [MþH]þ calcd. for C21H16N3OS
358.1014, found 358.1004.
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(pyridin-2-yl)prop-2-en-1-one (33)
Purified by column flash chromatography (0% / 40% ethyl ac-
etate in hexane) then by recrystallization of ethyl acetate and
hexane. Yield 11%, mp 187.5e188 C; IR (FTIR/FTNIR-ATR):
1664 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 9.00 (1H, d,
J¼ 1.2 Hz), 8.72 (1H, d, J¼ 4 Hz), 8.69 (1H, dd, J¼ 1.6 Hz, J¼ 5.2 Hz),
8.52 (1H, s), 8.18 (1H, d, J¼ 8 Hz), 8.14 (1H, d, J¼ 16 Hz), 8.03 (1H, d,
J¼ 7.6 Hz), 7.98e7.94 (1H, m), 7.90e7.86 (1H, m), 7.83e7.77 (1H, m),
7.54e7.34 (6H, m). 13C NMR (DMSO-d6, 400 MHz) d: 188.50, 153.43,
150.24, 149.71, 149.01, 148.84, 138.83, 137.73, 135.92, 133.89, 129.63,
129.15, 127.90, 127.55, 127.31, 123.93, 122.49, 120.80, 118.87, 118.14.




Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 82%, mp 204e204.6C; IR (FTIR/FTNIR-ATR):
1663 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 8.99 (1H, d,
J ¼ 1.6 Hz), 8.69 (1H, dd, J ¼ 1.6 Hz, J ¼ 5 Hz), 8.37 (1H, s), 8.01 (1H,
dt, J ¼ 2 Hz, J ¼ 5 Hz), 7.83e7.79 (3H, m), 7.56 (1H, dd, J ¼ 2 Hz,
J ¼ 8.4 Hz), 7.54e7.48 (3H, m), 7.44e7.35 (2H, m), 7.31 (1H, s), 6.87
(1H, d, J ¼ 8.4 Hz), 6.06 (2H, s). 13C NMR (DMSO-d6, 400 MHz) d:
186.40, 151.53, 149.93, 149.65, 148.74, 148.02, 138.85, 135.78, 132.76,
132.22, 129.73, 128.93, 127.94, 127.36, 124.64, 123.93, 121.78, 118.76,
118.27, 108.16, 107.67, 102.12. HRMS (m/z): [MþH]þ calcd. for
C24H18N3O3 396.1348, found 396.1344.
4.1.25. (E)-3-(1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-4-yl)-1-(1H-
pyrrol-3-yl)prop-2-en-1-one (35)
Purified by column flash chromatography (0%/ 2%methanol in
ethyl acetate). Yield 15%, mp 211.8e212.5 C; IR (FTIR/FTNIR-ATR):
1644 cm1 (C]O), 1H NMR (CDCl3, 400 MHz) d: 9.55 (1H, s), 9.00
(1H, s), 8.69 (1H, d, J ¼ 4.8 Hz), 8.36 (1H, s), 8.01 (1H, dd, J ¼ 2 Hz,
J ¼ 8 Hz), 7.83e7.79 (3H, m), 7.53e7.49 (2H, m), 7.44e7.35 (2H, m),
7.18 (1H, d, J ¼ 15.6 Hz), 7.09e7.08(1H, m), 6.95e6.93 (1H, m),
6.34e6.32 (1H, m). 13C NMR (DMSO-d6, 400 MHz) d: 177.48, 149.61,
148.76, 138.92, 135.81, 132.95, 129.79, 129.73, 128.60, 128.13, 127.28,
126.40, 123.96, 123.37, 118.75, 118.31, 116.78, 110.07. HRMS (m/z):
[MþH]þ calcd. for C21H17N4O 341.1402, found 341.1389.
4.1.26. (E)-1-(1H-indol-3-yl)-3-(1-phenyl-3-(pyridin-3-yl)-1H-
pyrazol-4-yl)prop-2-en-1-one (36)
Purified by column flash chromatography (0% / 30% ethyl ac-
etate in hexane). Yield 17%, mp 267.5e268 C; IR (FTIR/FTNIR-ATR):
1646 cm1 (C]O). 1H NMR (DMSO-d6, 400 MHz) d: 12.14 (1H, s),
9.33 (1H, s), 8.90 (1H, d, J ¼ 1.6 Hz), 8.71 (1H, dd, J ¼ 1.6, J ¼ 4.8 Hz),
8.51 (1H, s), 8.30 (1H, d, J¼ 6.8 Hz), 8.11 (1H, dt, J¼ 2, J¼ 8 Hz), 7.96
(2H, d, J ¼ 7.6 Hz), 7.78 (1H, d, J ¼ 15.2 Hz), 7.63e7.41 (6H, m),
7.27e7.20 (2H, m).13C NMR (DMSO-d6, 400 MHz) d: 183.26, 149.55,
149.52, 148.70,138.98, 136.87, 135.70,134.02, 129.75, 128.62,128.19,
128.15, 127.26, 125.76, 125.08, 123.94, 123.13, 121.85, 121.66, 118.75,




Purified by flash column chromatography (0% / 25% EtOAc in
Hexane). Yield 30%, mp 161e161.8C; IR (FTIR/FTNIR-ATR):
1664 cm1 (C]O), 1H NMR (CDCl3, 400 MHz) d: 8.99 (1H, d,
J¼ 1.2 Hz), 8.69 (1H, dd, J¼ 1.6 Hz, J¼ 5.2 Hz), 8.39 (1H, s), 8.02 (1H,
dt, J ¼ 2 Hz, J ¼ 8 Hz), 7.97e7.95 (2H, m), 7.83 (1H, d, J ¼ 15.6 Hz),
7.79 (2H, m), 7.59e7.38 (7H, m), 7.37 (1H, d, J ¼ 15.6 Hz). 13C NMR
(DMSO-d6, 400 MHz) d: 188.68, 150.05, 149.70, 148.76, 138.84,137.57, 135.82, 133.52, 133.14, 129.74, 129.11, 128.80, 128.22, 127.90,
127.39, 123.95, 121.90, 118.79, 118.17. Anal. calcd for C23H17N3O C,
78.61; H, 4.88; N, 11.96. found: C, 78.77; H, 4.85; N, 11.58. HRMS (m/
z): [MþH]þ calcd. for C23H18N3O 352.1450; found 352.1443.
4.1.28. (E)-3-(1-phenyl-3-(pyridin-3-yl)-1H-pyrazol-4-yl)-1-
(3,4,5-trimethoxyphenyl)prop-2-en-1-on (CAS No: 1287408-93-8)
(38)
Purified by flash column chromatography (0% / 25% EtOAc in
Hexane). Yield 21%, mp 115e116C; IR (FTIR/FTNIR-ATR):
1646 cm1 (C]O), 1H NMR (CDCl3) d: 8.99 (1H, d, J ¼ 1.2 Hz), 8.69
(1H, dd, J ¼ 1.6 Hz, J ¼ 5.2 Hz), 8.36 (1H, s), 8.02 (1H, dt, J ¼ 2 Hz,
J ¼ 8 Hz), 7.84 (1H, d, J ¼ 15.6 Hz), 7.54e7.34 (6H, m), 7.29 (1H, d,
J ¼ 15.6 Hz), 7.19 (2H, s), 3.92 (6H, s), 3.86 (3H, s). 13C NMR (DMSO-
d6, 400MHz) d: 187.51,152.91,149.99,149.72,148.81,142.02,138.84,
135.88, 133.36, 132.95, 129.75, 129.24,128.01, 127.44, 123.96, 121.82,
118.94, 118.22, 118.14, 106.03, 60.21, 56.23. Anal. calcd for
C26H23N3O4 C, 70.73; H, 5.25; N, 9.52; found: C, 70.95; H, 5.53; N,




Purified by flash column chromatography (0% / 20% EtOAc in
Hexane). Yield 22%, mp 206e207C; IR (FTIR/FTNIR-ATR):
1625 cm1 (C]O). 1H NMR (DMSO-d6, 400 MHz) d: 9.26 (1H, s),
8.73 (1H, d, J ¼ 2 Hz), 8.67 (1H, dd, J ¼ 1,6 Hz, J ¼ 4.8 Hz), 7.96e7.93
(3H, m), 7.59e7.54 (3H, m), 7.42e7.38 (1H, m), 7.16 (1H, d,
J¼ 16 Hz), 6.86 (1H, d, J¼ 16 Hz), 6.29 (2H, s), 3.81 (3H, s), 3.75 (6H,
s). 13C NMR (DMSO-d6, 400 MHz) d: 193.08, 161.90, 157.89, 149.63,
149.36, 148.53, 138.83,135.46, 133.98,129.66, 129.18, 128.92,127.84,
127.29, 123.85, 118.78, 117.46, 110.57, 90.86, 55.76, 55.44. Anal. calcd
for C26H23N3O4 C, 70.73; H, 5.25; N, 9.52; found: C, 70.92; H, 5.38; N,




Purified by flash column chromatography (0% / 25% EtOAc in
Hexane). Yield 28%, mp 91e92C; IR (FTIR/FTNIR-ATR):
1648 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 8.98 (1H, d,
J¼ 1.6 Hz), 8.67 (1H, dd, J¼ 1.6 Hz, J¼ 5.2 Hz), 8.33 (1H, s), 8.02 (1H,
dt, J ¼ 1.6 Hz, J ¼ 8 Hz), 7.79 (2H, m), 7.70 (1H, d, J ¼ 15.6 Hz),
7.53e7.37 (5H, m), 7.33 (1H, d, J ¼ 15.6 Hz), 6.75 (1H, d, J ¼ 8.8 Hz),
3.92 (3H, s), 3.91 (3H, s), 3.87 (3H, s). Anal. calcd. for C26H23N3O4 C,
70.73; H, 5.25; N, 9.52; found: C, 70.92; H, 5.17; N, 9.52. HRMS (m/z):
[MþH]þ calcd. for C26H24N3O4 442.1767; found 442.1765.
4.1.31. (E)-1-(3,4-Dimethoxyphenyl)-3-(1-phenyl-3-(pyridin-3-yl)-
1H-pyrazol-4-yl)prop-2-en-1-on (CAS No: 1002609-04-2) (41)
Purified by flash column chromatography (0% / 25% EtOAc in
Hexane). Yield 36%, mp 162e163C; IR (FTIR/FTNIR-ATR):
1655 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.97 (1H, s), 8.65
(1H, d, J ¼ 3.6 Hz), 8.34 (1H, s), 8.03 (1H, d, J ¼ 7.8 Hz), 7.79e7.77
(2H, m), 7.76 (1H, d, J ¼ 15.9 Hz), 7.55e7.33 (7H, m), 6.85 (1H, d,
J ¼ 7.8 Hz), 3.91 (6H, s). 13C NMR (DMSO-d6, 400 MHz) d: 186.85,
153.22, 149.88, 149.66, 148.82, 148.77, 138.87, 135.81, 132.46, 130.46,
129.73, 128.98, 128.02, 127.34, 123.93, 122.94, 121.85, 118.81, 118.26,
110.87, 110.64, 55.78, 55.57. Anal. calcd. for C25H21N3O3 C, 72.98; H,
5.14; N, 10.21; found: C, 72.49; H, 5.05; N, 10.03. HRMS (m/z):
[MþH]þ calcd. for C25H22N3O3 412.1661; found 412.1650.
4.1.32. (E)-1-(2,5-Dimethoxyphenyl)-3-(1-phenyl-3-(pyridin-3-yl)-
1H-pyrazol-4-yl)prop-2-en-1-on (42)
Purified by recrystallization from hexane-ethyl acetate mixture.
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1H NMR (DMSO-d6, 400MHz) d: 9.29 (1H, s), 8.82 (1H, d, J¼ 1.6 Hz),
8.69 (1H, d, J¼ 4.8 Hz), 8.04 (1H, d, J¼ 8.4 Hz), 7.96 (2H, d, J¼ 8 Hz),
7.59e7.39 (5H, m), 7.28 (1H, d, J ¼ 16 Hz), 7.13e7.07 (2H, m), 7.02
(1H, s), 3.80 (3H, s), 3.74 (3H, s). 13C NMR (DMSO-d6, 400 MHz) d:
191.72, 152.99, 151.50, 149.74, 149.68, 148.72, 138.81, 135.77, 133.13,
129.66, 129.21, 129.18, 127.98, 127.32, 126.64, 123.86, 118.85, 118.19,
117.80, 113.94, 113.59, 56.25, 55.53. Anal. calcd for C25H21N3O3 C,
72.98; H, 5.14; N, 10.21; found: C, 73.31; H, 5.57; N, 10.40. HRMS (m/
z): [MþH]þ calcd. for C25H22N3O3 412.1661; found 412.1649.
4.1.33. (E)-1-(2,4-Dimethoxyphenyl)-3-(1-phenyl-3-(pyridin-3-yl)-
1H-pyrazol-4-yl)prop-2-en-1-on (CAS No: 1002461-21-3) (43)
Purified by recrystallization from acetone-water mixture. Yield
34%, mp 130e131C; IR (FTIR/FTNIR-ATR): 1646 cm1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 9.01 (1H, s), 8.63 (1H, d, J ¼ 3.4 Hz), 8.24
(1H, s), 8.20 (1H, d, J ¼ 7.2 Hz), 7.73e7.68 (2H, m), 7.62 (1H, d,
J ¼ 15.6 Hz), 7.55e7.53 (2H, m), 7.46 (1H, t, J ¼ 7.8 Hz), 7.34e7.32
(1H, m), 7.31 (1H, d, J¼ 15.6 Hz), 6.52 (1H, d, J¼ 8.7 Hz), 6.43 (1H, d,
J ¼ 1.8 Hz), 3.81 (6H, s). 13C NMR (DMSO-d6, 400 MHz) d: 189.16,
163.83, 159.99, 149.61, 148.78, 138.87, 135.84, 131.96, 131.27, 129.64,
129.00, 128.16, 127.24, 126.88, 123.88, 121.28, 118.87, 118.10, 105.89,
98.50, 55.88, 55.57. Anal. calcd. for C25H21N3O3 C, 72.98; H, 5.14; N,
10.21; found: C, 73.33; H, 5.38; N, 10.21. HRMS (m/z): [MþH]þ calcd.
for C25H22N3O3 412.1661; found 412.1643.
4.1.34. (E)-3-(1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-1-
(thiophen-3-yl)prop-2-en-1-one (44)
Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane) then by recrystallization of ethyl acetate and
hexane. Yield 54%, mp 219e220C; IR (FTIR/FTNIR-ATR):
1655 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 8.74 (2H, d,
J ¼ 6 Hz), 8.36 (1H, s), 8.08 (1H, d, J ¼ 2.8 Hz), 7.90 (1H, d,
J ¼ 15.6 Hz), 7.79 (2H, d, J ¼ 7.6 Hz), 7.67e7.62 (3H, m), 7.52 (2H, t,
J ¼ 8 Hz), 7.41e7.36 (2H, m), 7.26 (1H, d, J ¼ 15.6 Hz). 13C NMR
(DMSO-d6, 400 MHz) d: 182.68, 150.26, 149.94, 142.76, 139.28,
138.76, 133.55, 132.13, 129.75, 129.15, 127.84, 127.53, 126.91, 123.74,




Purified by column flash chromatography (0% / 50% ethyl ac-
etate in hexane). Yield 60%, mp 148.2e148.8C; IR (FTIR/FTNIR-
ATR): 1656 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 8.73 (2H, d,
J ¼ 5.6 Hz), 8.36 (1H, s), 7.87 (1H, d, J ¼ 15.2 Hz), 7.80 (2H, d,
J ¼ 7.6 Hz), 7.66 (2H, d, J ¼ 6 Hz), 7.59e7.50 (4H, m), 7.38e7.34 (2H,
m), 6.88 (1H, d, J ¼ 8.4 Hz), 6.06 (2H, s). 13C NMR (DMSO-d6,
400 MHz) d: 186.37, 151.47, 150.17, 149.85, 147.95, 139.27, 138.73,
132.41, 132.14, 129.63, 129.13, 127.40, 124.57, 122.52, 122.25, 118.79,
118.36, 108.07, 107.60, 102.03. HRMS (m/z): [MþH]þ calcd. for
C24H18N3O3 396.1348, found 396.1338.
4.1.36. (E)-3-(1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-1-(1H-
pyrrol-3-yl)prop-2-en-1-one (46)
Purified by column flash chromatography (0%/ 6%methanol in
dichloromethane). Yield 28%, mp 258e258.6C; IR (FTIR/FTNIR-
ATR): 1645 cm1 (C]O). 1H NMR (CDCl3, 400 MHz) d: 9.62 (1H, bs),
8.74 (2H, d, J ¼ 4.2 Hz), 8.35 (1H, s), 7.87 (1H, d, J ¼ 15.6 Hz), 7.80
(2H, d, J ¼ 7.6 Hz), 7.67 (2H, d, J ¼ 4.4 Hz), 7.53 (2H, t, J ¼ 8 Hz),
7.40e7.36 (1H, m), 7.20 (1H, d, J¼ 15.6 Hz), 7.10 (1H, s), 6.96 (1H, m),
6.35e6.33 (1H, m).13C NMR (DMSO-d6, 400 MHz) d: 177.44, 150.25,
149.65, 139.51, 138.83, 132.93, 129.72, 129.54, 128.85, 127.41, 126.45,
123.83, 122.64, 118.83, 118.49, 116.89, 110.07. HRMS (m/z): [MþH]þ
calcd. for C21H17N4O 341.1402, found 341.1400.4.1.37. (E)-1-phenyl-3-(1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-4-
yl)prop-2-en-1-one (CAS No:1390831-45-4) (47)
Purified by flash column chromatography (0% / 25% EtOAc in
Hexane). Yield 36%, mp 215e216 C; IR (FTIR/FTNIR-ATR):
1656 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.70 (2H, d,
J ¼ 4.5 Hz), 8.37 (1H, s), 7.96 (2H, d, J ¼ 7.5 Hz), 7.86 (2H, d,
J ¼ 15.6 Hz), 7.78e7.69 (2H, m), 7.58e7.36 (3H, m), 7.58e7.36 (4H,
m), 7.22e7.20 (1H, m). 13C NMR (DMSO-d6, 400 MHz) d: 188.66,
150.27, 150.07, 139.27, 138.76, 137.52, 133.24, 133.14,
129.74,129.35,128.20, 128.24, 127.52, 122.65, 122.32, 118.85, 118.32.
Anal. calcd. for C23H17N3O C, 78.61; H, 4.88; N, 11.96. found C, 78.25;
H, 4.85; N, 11.82. HRMS (m/z): [MþH]þ calcd. for C23H18N3O
352.1450; found 352.1447.
4.1.38. (E)-3-(1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-1-
(3,4,5-trimethoxyphenyl)prop-2-en-1-on (CAS No: 1390911-60-0)
(48)
Purified by flash column chromatography (0% / 25% EtOAc in
Hexane). Yield 18%, mp 161e162C; IR (FTIR/FTNIR-ATR):
1656 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.67 (2H, bs), 8.34
(1H, s), 7.84 (1H, d, J ¼ 15.6 Hz), 7.75e7.70 (4H, m), 7.49e7.36 (3H,
m), 7.33 (1H, d, J ¼ 15.6 Hz), 7.16 (2H, s), 3.87 (9H, s). 13C NMR
(DMSO-d6, 400 MHz) d: 187.40, 152.91, 150.27, 150.05, 142.08,
139.40,138.76,133.03,132.90,129.76,129.44,127.56,122.72,122.22,
119.02, 118.30, 106.08, 60.21, 59.72, 56.23. Anal. calcd. for
C26H23N3O4 C, 70.73; H, 5.25; N, 9.52. found C, 70.34; H, 5.63; N,




Purified by recrystallization from ethanol-water mixture. Yield
68%, mp 192e193C; IR (FTIR/FTNIR-ATR): 1636 cm1 (C]O). 1H
NMR (DMSO-d6, 400 MHz) d: 9.26 (1H, s), 8.71 (2H, d, J¼ 6 Hz), 7.94
(2H, d, J ¼ 8 Hz), 7.57 (2H, t, J ¼ 8 Hz), 7.52 (2H, d, J ¼ 5.6 Hz),
7.43e7.40 (1H, m), 7.21 (1H, d, J ¼ 16 Hz), 6.89 (1H, d, J ¼ 16 Hz),
6.33 (2H, s), 3.83 (3H, s), 3.75 (6H, s). 13C NMR (DMSO-d6, 400 MHz)
d: 193.13, 161.97, 157.89, 150.16, 149.48, 139.21, 138.76, 133.82,
129.68, 129.51, 129.11, 127.43, 122.39, 118.87, 117.66, 110.54, 90.89,
55.79, 55.74. Anal. calcd. for C26H23N3O4 C, 70.73; H, 5.25; N, 9.52.
found: C, 70.42; H, 5.36; N, 9.41. HRMS (m/z): [MþH]þ calcd. for
C26H24N3O4 442.1767; found 442.1758.
4.1.40. (E)-3-(1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-1-
(2,3,4-trimethoxphenyl)prop-2-en-1-on (50)
Purified by flash column chromatography (0% / 25% EtOAc in
Hexane). Yield 30%, mp 160e161C; IR (FTIR/FTNIR-ATR):
1654 cm1 (C]O). 1H NMR (CDCl3, 300 MHz) d: 8.66 (2H, d,
J ¼ 6 Hz), 8.27 (1H, s), 7.74e7.68 (5H, m), 7.48e7.35 (4H, m), 7.33
(1H, d, J¼ 15.6 Hz), 6.70 (1H, d, J¼ 8.7 Hz), 3.87 (3H, s), 3.86 (3H, s),
3.83 (3H, s). 13C NMR (DMSO-d6, 400MHz) d: 189.76,156.56,152.75,
150.22, 149.87, 141.65, 139.40, 138.77, 132.28, 129.67, 129.15, 127.45,
126.71, 126.11, 125.07, 122.69, 118.95, 118.10, 107.88, 61.83, 60.53,
56.08. Anal. calcd. for C26H23N3O4 C, 70.73; H, 5.25; N, 9.52. found: C,
70.47; H, 5.12; N, 9.37. HRMS (m/z): [MþH]þ calcd. for C26H24N3O4
442.1767; found 442.1781.
4.1.41. (E)-1-(3,4-Dimethoxyphenyl)-3-(1-phenyl-3-(pyridin-4-yl)-
1H-pyrazol-4-yl)prop-2-en-1-on (CAS No: 1147371-58-1) (51)
Purified by recrystallization from acetone-water mixture. Yield
44%, mp 190e191C; IR (FTIR/FTNIR-ATR): 1653 cm1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 8.68 (2H, bs), 8.34 (1H, s), 7.83 (1H, d,
J ¼ 15.6 Hz), 7.76e7.69 (4H, m), 7.55e7.20 (5H, m), 6.87 (1H, d,
J ¼ 9 Hz), 3.92 (3H, s), 3.91 (3H, s). 13C NMR (DMSO-d6, 400 MHz) d:
186.83,153.26,150.26,149.93, 148.84, 139.40,138.80,132.18, 130.43,
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110.65, 55.80, 55.58. Anal. calcd for C25H21N3O3 C, 72.98; H, 5.14; N,
10.21. found: C, 72.58; H, 5.12; N, 10.05. HRMS (m/z): [MþH]þ calcd.
for C25H22N3O3 412.1661; found 412.1651.4.1.42. (E)-1-(2,5-Dimethoxyphenyl)-3-(1-phenyl-3-(pyridin-4-yl)-
1H-pyrazol-4-yl)prop-2-en-1-on (52)
Purified by recrystallization from acetone-water mixture. Yield
32%, mp 136e137C; IR (FTIR/FTNIR-ATR): 1656 cm1 (C]O). 1H
NMR (DMSO-d6, 400 MHz) d: 9.30 (1H, s), 8.73 (2H, d, J ¼ 5.2 Hz),
7.96 (2H, d, J ¼ 8 Hz), 7.63 (2H, d, J ¼ 6 Hz), 7.60e7.56 (2H, m), 7.50
(1H, d, J ¼ 16 Hz), 7.44e7.40 (1H, m), 7.32 (1H, d, J ¼ 16 Hz),
7.15e7.09 (2H, m), 7.04 (1H, d, J ¼ 2.8 Hz), 3.81 (3H, s), 3.75 (3H, s).
13C NMR (DMSO-d6, 400 MHz) d: 191.69, 153.01, 151.56, 150.14,
149.86, 139.43, 138.75, 132.83, 129.68, 129.33, 129.21, 127.47, 127.07,
122.68, 118.95, 118.19, 117.98, 114.01, 113.65, 56.30, 55.55. Anal.
calcd. for C25H21N3O3 C, 72.98; H, 5.14; N, 10.21. found: C, 72.87; H,
5.12; N, 9.88. HRMS (m/z): [MþH]þ calcd. for C25H22N3O3 412.1661;
found 412.1641.4.1.43. (E)-1-(2,4-Dimethoxyphenyl)-3-(1-phenyl-3-(pyridin-4-yl)-
1H-pyrazol-4-yl)prop-2-en-1-on (CAS No: 1147368-37-3) (53)
Purified by recrystallization from acetone-water mixture. Yield
36%, mp 182e183C; IR (FTIR/FTNIR-ATR): 1644 cm1 (C]O). 1H
NMR (CDCl3, 300 MHz) d: 8.66 (2H, d, J ¼ 4.5 Hz), 8.22 (1H, s),
7.73e7.67 (6H, m), 7.48e7.43 (2H, m), 7.37e7.32 (2H, m), 6.50 (1H,
dd, J ¼ 2.1 Hz, J ¼ 8.7 Hz), 6.42 (1H, d, J ¼ 2.4 Hz), 3.80 (3H, s), 3.79
(3H, s). Anal. calcd for C25H21N3O3 C, 72.98; H, 5.14; N, 10.21. found:
C, 72.67; H, 5.12; N, 9.98. HRMS (m/z): [MþH]þ calcd. for
C25H22N3O3 412.1661; found 412.1642.4.2. Biological evaluation
4.2.1. Cells culture
Hepatocellular carcinoma cell lines (Huh7, HepG2 and Mah-
lavu), human breast carcinoma cells (MCF7) and human colon
carcinma cells (HCT116) were grown in Dulbecco's Modified Eagles
Medium (DMEM) supplemented with 10% fetal bovine serum
(Invitrogen GIBCO), 1% non-essential amino acids (GIBCO, Invi-
trogen) and SNU-475 were grown in RPMI-1640 media (Invitrogen
GIBCO) supplemented with 10% FBS, 2 mM L-glutamine. MCF12A,
human breast epithelial cells, were grown in DMEM/HAMS F12
media (Invitrogen GIBCO) supplemented with 10% FBS, 1% NEAA,
100 ng/ml EGF, 500 ng/ml hydrocortisone, and 10 mg/ml insulin.
MRC-5, human fetal lung fibroblast cells, were maintained in
Minimum Essential Medium (MEM) (Invitrogen GIBCO), with 10%
fetal bovine serum (FBS), 2 mM L-glutamine. All media contained
100 units/ml penicillin and streptomycin and cells weremaintained
at 37 C in a humidified incubator under 5% CO2.4.2.2. NCI-60 sulforhodamine B assay
Cells were plated in 96-well plates (2000e3000 cell/well in 150
ml/well) and grown for 24 h at 37 C. Treatment of cells with the
compounds (dissolved in DMSO) was done in a concentration range
of 40 mM-0.3 mM (in triplicates). After 72 h of incubation, cells were
fixed with 10% (v/v) trichloroacetic acid (MERCK) for an hour and
stained with sulforhodamine B (SRB) solution (50 ml of a 0.4% (m/v)
of SRB in 1% acetic acid solution). For the removal of unbound SRB,
cells werewashedwith 1% acetic acid and left for air-drying. Protein
bound SRB was solubilized in 10 mM Tris-base prior to absorbance
measurement (515 nm) using 96-well plate reader. Cells treated
with DMSO alone were used as controls for percent inhibition and
IC50 calculations.4.2.3. Real-time cell growth surveillance by electronic sensing (RT-
CES)
Real-time cell growth was monitored using the xCELLigence
System (Roche Applied Sciences). Human cancer cell lines
(1000e3000 cells/well) were seeded into 96-well E-plates. The
proliferation of cells were monitored every 30 min for 24 h after
seeding, (when cells were in log growth phase) treatments with the
compounds were done. The cell index (CI) values were recorded
every 10 min for the first 24 h and then every 30 min for the
remaining 48 h. The cell growth ratios were calculated by CIdrug/
CIDMSO.
4.2.4. Detection of apoptosis
Cells were seeded onto coverslips in 6-well plates. After 24 h in
culture, cells were treated with the compounds with their IC50
concentrations. After 48 h, apoptotic cells were identified by
Annexin-V-Fluos (Roche) and DAPI (Santa Cruz) staining according
to the manufacturer's recommendations (Roche). Cells were then
analyzed using the fluorescence microscope (Nikon Eclipse 50i).
4.2.5. Flow cytometry for cell cycle analysis
Cells were seeded onto 100 mm culture dishes. After 24 h, cells
were treated with the compounds with their IC100 concentrations.
Cells were fixed with ice-cold 70% ethanol for 3 h at 20 C after
24 h, 48 h and 72 h of incubation. Cell cycle analysis was carried out
by PI (Propidium Iodide) staining using MUSE Cell Analyzer ac-
cording to the manufacturer's recommendations (Millipore).
4.2.6. Western blot analysis
Human cancer cell lines were treatedwith the compounds (IC100
concentrations) or with DMSO control for 24 h. Novex® NuPAGE®
Bis-Tris Electrophoresis system was used according to the manu-
facturer's protocol for all the western blotting analysis. For gel
electrophoresis (NuPAGE), 20e50 mg of protein was used per well.
Then the proteins were transferred to nitrocellulose membrane via
XCell IITM Blot Module. Cyclin-B1 (#554177, BD), Cdc2/Cdk1
(#PC25, Calbiochem), phospho-Cyclin-B1 (Ser147) (bs-3122R, Bio-
ss), p21/WAF1/Cip1 (#05e345, Millipore), p53 (#05e224, Milli-
pore), phospho-p53 (Ser15) (#9286S, Cell Signaling), Rb (#sc102,
Santa Cruz), and phospho-Rb (Ser807/811) (#9308S Cell Signaling)
antibodies were used in 1:200 to 1:500 5% BSA-TBS-T. b-actin
(#A5441, Sigma) antibody was used for equal loading.
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